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Abstract: B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and 
survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus 
erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence 
of efficacy in several preclinical and clinical studies in SLE. Two recent large randomized 
controlled trials yielded a significant positive effect of the drug compared to placebo in patients 
with active disease. In this review, we discuss basic aspects of B-cell and BLyS biology in SLE 
and summarize the evidence supporting a role of belimumab in SLE, from animal studies to 
phase III clinical trials.
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Introduction
It has been more than 50 years since a new medication was approved by the Food 
and Drug Administration (FDA) for the treatment of lupus.1 Although several of 
the examined biologics have yielded promising results in open-label studies, none 
showed a considerable effect in randomized controlled trials (RCT), sufficient to 
pass the   rigorous scientific FDA standards of approval.2 The genetic and phenotypic 
  heterogeneity characteristic of systemic lupus erythematosus (SLE), the frequently 
undulating   disease activity causing difficulties capturing a response, and the 
  confounding effect of background immunosuppressive treatments are considered the 
main reasons for this failure.1 These notions were well illustrated in the two phase III 
rituximab trials in SLE that failed to show clinical benefit, despite wide preliminary 
evidence of efficacy.3
In this discouraging scene of biologics in SLE, hope has been raised by the 
modest yet promising results yielded by belimumab, a fully human recombinant 
  immunoglobulin G (IgG)1λ monoclonal antibody to soluble B-lymphocyte stimulator 
(BLyS).4 Belimumab is the first and only biologic to show consistent efficacy in two 
large phase III RCTs in SLE. Extension arms of these trials are ongoing with projected 
completion in December 2010, when a pending priority FDA review may grant the 
medication regulatory approval in the United States.
B cells in SLE
SLE, the prototypic autoimmune disease, is associated with numerous abnormalities 
in B-cell development, maturation, and function.5 Immune deregulations in SLE are 
characterized by loss of tolerance to ubiquitous self antigens and are propagated by 
multiple interactions between innate and adaptive immune pathways, culminating in Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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end-organ damage.6 Immature transitional cells, memory cells, 
and plasma cells expand in the periphery, and   autoreactive cells 
are incompletely deleted in the bone marrow of SLE patients.5 
Overactive T-cell-dependent germinal center (GC)-like 
  reactions produce expanded and largely unregulated   numbers 
of memory B cells and plasma cells.5 Once tolerance is   broken, 
autoreactive B cells can perpetuate disease, not only through 
autoantibody production and immune complex deposition, but 
also by multiple other effector functions. Such B-cell func-
tions include   production of cytokines, antigen presentation to 
T cells, induction of epitope spreading, and amplification of 
tissue-specific   autoimmune responses.7
Biology of BLyS
BLyS, also known as B-cell-activating factor (BAFF), is 
a 285-amino acid cytokine with a central physiologic role 
in B-cell homeostasis and survival.8 BLyS and its closely 
related homologue APRIL (a proliferation-inducing ligand) 
are members of the tumor necrosis factor (TNF) superfamily 
expressed by a variety of cell types, mainly innate immune 
cells, like neutrophils, macrophages, monocytes, and 
d  endritic cells, but also some T and B lymphocytes.9 Several 
other nonhematopoietic cells expressing these cytokines 
have been recently identified, possibly modulating B-cell 
functions in the tissue microenvironment.9 Both BLyS and 
APRIL are synthesized as membrane-spanning monomers 
and associate to form homotrimers that are proteolytically 
processed to soluble ligands.8,9 BLyS can be also found in a 
membrane-bound form.9
BLyS  interacts  with  three  different  receptors: 
BR3 (BAFF receptor 3), also known as BAFF receptor, 
TACI   (transmembrane activator and calcium modulator and 
cyclophylin ligand interactor), and BCMA (B-cell   maturation 
antigen).9 BR3 binds solely to BLyS, whereas TACI and 
BCMA ligate both BLyS and APRIL. All three receptors 
  signal through TNF receptor–associated factors (TRAFs), 
activating the nuclear factor-kB (NF-kB) and other 
  pathways.9 BR3 is a potent stimulator of the alternative 
NF-kB pathway, whereas TACI and BCMA stimulate the 
classic NF-kB   pathway. Receptor specificities, affinities, 
and signal transduction pathways have been reviewed else-
where.8,9   Variations in receptor-ligand affinities and distinct 
patterns and levels of receptor expression among different 
stages of B-cell development link them to a wide array of 
biological effects. BR3 expression is low in newly formed 
immature B cells, but progressively increases throughout 
B-cell development and is universal in mature B cells.8 TACI 
is also an inducible receptor, expressed by all peripheral 
B cells. On the other hand, BCMA expression is restricted to 
  antibody-producing cells.8 These receptors are also expressed 
in several other immune and nonimmune cell types.9
In the early stages of B-cell development, BLyS binding 
to BR3 provides an important survival signal by antagonizing 
apoptosis and allowing further differentiation and entrance 
of transitional cells into mature B-cell pools.8 BR3 expres-
sion, and thus the capacity to bind BLyS, rises in parallel 
with expression of the B-cell receptor (BCR). As basal BCR 
signaling is also required for positive selection of healthy 
B-cells and low-affinity autoreactive B cells, both   pathways 
affect the stringency of naive B-cell selection in the periphery.8 
Antigen-experienced B-cell subsets are   however independent 
of the BLyS/BR3 interaction,   relying on TACI and BCMA for 
maturation and differentiation signals.8 TACI is essential for 
efficient T-cell-independent type II humoral immune responses 
that yield antibody-producing   plasmablasts and short-lived 
plasma cells.8 Although BLyS and APRIL are not required for 
generation of T-cell-dependent GCs, they play a role in appro-
priate evolution of the overall GC   reactions that yield long-lived 
plasma cells and memory cells.   TACI–APRIL interactions 
affect B-cell survival and class switching (CD 40 independent) 
to IgA during   T-cell-dependent responses.9 Long-lived plasma 
cells in the bone marrow primarily express BCMA, which pro-
motes their survival and function through ligation of APRIL or 
BLyS.8 In contrast, most evidence supports a lack of reliance 
of memory B cells on BLyS or APRIL for their survival or   
reactivation.8
BLyS in SLe
Lupus-prone mice have provided a valuable tool for 
  studying the effects of BLyS excess and BLyS blockade 
to   immunologic parameters and clinical manifestations of 
SLE. BLyS transgenic mice develop B-cell   hyperplasia, 
hypergammaglobulinemia, autoantibodies, including 
  antinuclear and anti-double-stranded DNA (anti-dsDNA) 
antibodies, and autoimmune symptoms reminiscent of SLE 
or Sjogren’s syndrome.10 Conversely, application of selec-
tive or   nonselective BLyS blockade in lupus-prone mice 
attenuates inflammation and even induces remission of 
nephritis in some strains.7 Selective blockade of BLyS in 
New Zealand black/white (NZB/W) F1 mice, the prototypical 
model of SLE nephritis, effectively depleted splenic B cells, 
sparing B1 and T1 cells.7 Although spontaneous GCs still 
formed and pathogenic autoantibodies were produced in 
these mice, long-lasting effects on splenic architecture and 
on B-cell-dependent accumulation of T cells and dendritic 
cells were observed.7 BLyS-specific blockade in NZB/W F1,   Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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NZW/BXSB F1, and NZM2410 mice significantly 
reduced the amount of target-organ damage, without 
preventing the emergence or deposition of pathogenic 
  autoantibodies.11–13 Similarly, in autoimmune-resistant MHC-
deficient C57BL/6 (B6) mice, BLyS overexpression led to 
humoral   a  uto  immunity;   however, renal immunopathology 
and clinical disease did not   develop.14 These observations 
suggest that target-organ   damage in SLE depends not only 
on tissue deposition of immune globulins and complement, 
but also on the   inflammatory burden imposed by activated 
cells and their inflammatory mediators.7 Only in the pres-
ence of a certain inflammatory microenvironment or an 
  autoimmunity-susceptible genetic background would a BLyS-
driven immunopathology progress to clinical disease.13
In accordance with observations in mice, administration 
of belimumab for 26 weeks in cynomolgus monkeys yielded 
a 50%–60% B-cell reduction, most significant in the mature 
B-cell subset, accompanied by decrease in size of the splenic 
lymphoid follicles. Reductions were observed at 4–8 weeks 
and were persistent after cessation of treatment, with return 
to baseline at 52 weeks.15
Among 185 patients with various systemic   autoimmune 
diseases, 95 of whom had SLE, 20% had   significantly ele-
vated plasma BLyS levels compared to healthy   controls, and 
levels of BLyS correlated with IgG levels and   anti-dsDNA 
titers.16 Elevated serum BLyS and blood BLyS messenger 
ribonucleic acid (mRNA) levels were demonstrated in 
50%–61% of longitudinally followed SLE patients.17 Serum 
BLyS levels correlated with anti-dsDNA titers in patients 
with detectable anti-dsDNA in the same study. In addition, 
BLyS concentrations seem to be related to disease activity in 
patients with SLE, as measured by SELENA-SLEDAI (SS).18 
BLyS mRNA levels have been proposed as a better marker 
of disease activity than serum protein levels.19
Clinical trials of belimumab  
in SLe: phases i and ii
A phase I dose-ranging RCT in 70 SLE patients with stable 
disease activity was the first to demonstrate belimumab’s 
in vivo safety and provide insight into its pharmacokinetic 
properties and biological activity.20 Belimumab’s long elimina-
tion half-life, slow clearance, and small volume of distribution 
are consistent with a fully human monoclonal antibody.20
A phase II double-blind RCT subsequently examined 
the safety, tolerability, biological activity, and efficacy of 
the drug in 449 SLE patients and a SS score $4.21 Subjects 
were assigned to either belimumab (1, 4, and 10 mg/kg) or 
placebo, administered intravenously on days 0, 14, and 28 
and every 28 days for 52 weeks. All subjects also received 
standard of care treatment, with a stable   regimen of steroids, 
antimalarials, or immunosuppressants for 60 days prior to 
the first belimumab dose. No significant differences between 
treatment and placebo groups were attained for either of 
the coprimary endpoints (% change in the SS score at 24 
weeks and the time to first SLE flare), and no dose response 
was observed. The time to first flare at weeks 24–52 was 
however prolonged with belimumab (154 days in the com-
bined belimumab group compared to 104 days in placebo, 
P = 0.036), suggesting that the drug can stabilize disease, 
but requires some time to do so. Significant decrease in mean 
physician’s global assessment (PGA) score at 52 weeks was 
noted (31% with belimumab compared to 14% in placebo, 
P = 0.0019).
Post-hoc analysis of the subgroup of patients with   
  serologically active disease (anti-nuclear autoantibodies 
[ANA] $1:80 and/or   anti-dsDNA $30 IU/mL) yielded sig-
nificantly better responses at 52 weeks in belimumab- versus 
placebo-treated patients in SS score, PGA, and short form 
36 (SF-36) physical component score (PCS).21 This patient 
subgroup had significantly more historic SLE criteria (renal, 
hematologic, and immunologic) and higher disease activ-
ity at baseline compared to ANA-negative patients.22 More 
patients in the ANA-positive group had detectable BLyS 
levels, whereas this group also had lower serum complement 
(P , 0.0001), higher immunoglobulin levels (P # 0.001), 
and increased number of CD19+/27+/38++ plasma cells 
(P = 0.1), all being suggestive of disease activity due to 
B-cell dysfunction.22
Critical analysis of the phase II belimumab trial data 
led to creation of the SLE responder index, a novel robust 
tool that could better define clinical meaningful changes 
in disease activity and be used as the primary endpoint 
in SLE trials.23 In this compound index, SS scores were 
utilized to define global improvement, British Isles Lupus 
Assessment Group (BILAG) domain scores to ensure no 
significant worsening in previously unaffected systems, 
and PGA to ensure that improvement in disease activity 
was not achieved to the detriment of the patient’s overall 
condition. The systemic response index (SRI) was defined 
by: $4-point reduction from baseline in SS score, no new 
A or $2 B BILAG organ domain scores, and no $0.3-point 
deterioration from baseline in PGA. BILAG scores A and B, 
respectively, indicate a severe and moderate flare in any of 
the eight organ domains of the index, which was designed 
based on the physician’s intention to treat.24 By   retrospective 
application of the SRI in the seropositive patients of the   Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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phase II belimumab trial, treatment with belimumab yielded 
a 46% response at week 52, compared to 29% in the placebo 
group (P = 0.006). SRI responses remained independent of 
baseline autoantibody subtype.23 This index fulfilled the 
FDA-suggested criteria for clinical endpoints in RCT in 
SLE25 and was approved by regulatory authorities as the 
primary endpoint for two large phase III studies of beli-
mumab, belimumab international SLE study (BLISS)-52 and 
BLISS-76, with the potential to be used again in similarly 
designed clinical trials.
Clinical trials of belimumab  
in SLe: phase iii
Promising results of the phase II belimumab trial   encouraged 
two larger global phase III trials of belimumab versus 
placebo, which recruited seropositive (ANA $1:80 or 
  anti-dsDNA $30 IU/mL at study entry) SLE patients 
with stable disease receiving standard of care treatment.26 
Patients had a SS score $6 and were stable on standard of 
care therapy for $30 days upon study entry. In both studies, 
patients were randomized to belimumab (1 or 10 mg/kg) 
or placebo on days 0, 14, and 28 and every 28 days for 48 
weeks. BLISS-52 (NCT00424476)27 was conducted between 
May 2007 and July 2009 and included 865 SLE patients 
enrolled in North America and Western and Central Europe. 
BLISS-76 (NCT00410384)28 was conducted between 
February 2007 and February 2010 enrolling 819 patients 
in Central and   Eastern Europe, Latin America, and Asia 
Pacific. Disease activity was assessed by SS, BILAG, and 
the SS Flare Index (SFI). SS and BILAG domain scores were 
measured every 4 weeks.29 In accordance with the EULAR 
guidelines,   health-related quality of life was assessed by 
use of the SF-36 domain, Physical and Mental Component 
Summary (PCS and MCS) scores, and the FACIT-Fatigue 
questionnaire.30 The primary endpoint in both trials was the 
SRI at 52 weeks. Secondary endpoints included the percent-
age of subjects with a 4-point reduction from baseline in SS 
score at 52 weeks, the mean change in PGA at 24 weeks, the 
mean change in SF-36 PCS at 24 weeks, and the percent-
age of subjects taking 7.5 mg/d of prednisone at baseline 
whose average prednisone dose was reduced by $25% or to 
#7.5 mg/day during weeks 40–52. The SRI at 76 weeks was 
an additional secondary endpoint in BLISS-76. Intention to 
treat principles was followed in data analysis.
Mean values of baseline disease characteristics were similar 
across the belimumab and placebo groups within each study, 
though variations were observed among the BLISS-52 and 
BLISS-76 cohorts (Table 1).31–33 Disease   duration was longer 
Table 1 Mean values of baseline disease characteristics of SLe 
patients in the BLiSS-52 and BLiSS-76 trials
Mean baseline  
characteristics
BLISS-52 BLISS-76 Combined   
cohort
Disease duration, years 5.3 7.5 6.4
SeLeNA-SLeDAi 9.8 9.7 9.7
BiLAG 1A/2B, % 58 64 61
ANA positive, % 95 92
Anti-dsDNA positive, % 75 64 69.4
Proteinuria  
(0.5 gr/24 h), %
25 16 20.1
Low C4, % 59 53 56.1
Antimalarial use, % 67 63 65.3
Prednisone equivalent  
dose $7.5 mg/day, %
69 46 58.0
immunosuppressant  
use, %
42 56 48.7
Note: values were similar across treatment groups for each trial.
Abbreviations: SLe, systemic lupus erythematosus; BLiSS, belimumab international 
SLe study.
in BLISS-76 (7.5 vs 5.3 years in BLISS-52).   Serologically, 
active lupus by means of anti-dsDNA antibody positiv-
ity was more frequent in BLISS-52, but more details on 
patient’s baseline immunologic characteristics have not yet 
been published. SS and BILAG organ system involvement at 
baseline were generally similar in the belimumab and placebo 
groups and between studies.29 The most common SS domains 
involved were dermal (82%), immunologic (80%), musculo-
skeletal (65%), and renal (16%). The most common BILAG 
domains involved were musculoskeletal (60%), mucocuta-
neous (59%), hematology (16%), renal (11%), and general 
(11%).29 Use of background medications differed at baseline, 
with higher steroid and lower immunosuppressant use in 
BLISS-52   indicating different approaches to therapy among 
different institutions and treatment locations.   Disclosures 
on the BLISS trials design and results would be helpful, as 
data have been presented in abstract form and through the 
manufacturer’s website to date, without getting subject to the 
rigors of peer-reviewed publications.
A significantly higher rate of SRI at 52 weeks was 
noted for both belimumab groups compared to placebo 
in BLISS-52. This was reached at 24–28 weeks and was 
sustained throughout the study (Table 2).26,31 Combined 
analysis of the two BLISS trials yielded significant differ-
ences in SRI rates at week 52 for both belimumab groups 
compared to placebo (Table 3).33 Effects in BLISS-76 were, 
however, only modest, with significantly higher SRI rates at 
52 weeks reached only in the 10 mg/kg belimumab group 
(P = 0.02 compared to placebo) and not sustained at 76 weeks 
(Table 4).26,32,34 Post hoc exploratory analyses using 4-point Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 3 Combined efficacy results of BLISS-52 and BLISS-76
Endpoints SOC + placebo  
(N = 562)
SOC + belimumab  
1 mg/kg (N = 559)
P SOC + belimumab  
10 mg/kg (N = 563)
P
SRi at week 52, n (%) 218 (38.8) 258 (46.2) ,0.01 285 (50.6) ,0.0001
• SS $ 4-point reduction (%) 230 (40.9) 269 (48.1) ,0.01 297 (52.8) ,0.05
• #0.3-point PGA worsening (%) 372 (66.2) 424 (75.8) ,0.001 420 (74.6) ,0.01
• No new 1A/2B BiLAG (%) 389 (69.2) 429 (76.7) ,0.01 425 (75.5) ,0.05
Mean % PGA improvement at week 24 24.3 28.8 ns 32.3 ,0.01
Mean % PGA improvement at week 52 27.1 36.7 ,0.01 37.8 ,0.001
SFI flare, % (HR)/median time to  
first flare, days
81.5/84 74.6 (0.82)/110 ,0.01 74.6 (0.84)/110 ,0.05
Severe SFI flare, % (HR) 23.7 17.0 (0.71) ,0.05 15.6 (0.64) ,0.01
New 1A/2B BiLAG, % (HR) 32.0 27.2 (0.83) ns 24.9 (0.75) ,0.05
New 1A BiLAG, % (HR) 23.1 19.0 (0.81) ns 16.2 (0.67) ,0.01
Prednisone dose reduction from  
7.5 mg/day at baseline, by 25% or to 
#7.5 mg/day, during weeks 40–52, n (%)
39 (12.3) 67 (20.1) ,0.01 58 (17.9) ,0.05
Prednisone dose increase from  
#7.5 to 7.5 mg/day at week 52, n (%)
82 (33.6) 58 (25.8) ns 62 (25.9) ns
SF-36 PCS change from baseline at  
week 52, mean (SD)
+2.9 (0.3) +4.3 (0.4) ,0.01 +3.8 (0.3) ,0.05
FACiT-fatigue score change from  
baseline at week 52, mean (SD)
+2.5 (0.4) +4.8 (0.4) ,0.001 +4.7 (0.4) ,0.001
Abbreviations: BLiSS, belimumab international SLe study; SRi, systemic response index; SS, SeLeNA-SLeDAi; PGA, physician’s global assessment; HR, hazard ratio;   
SD, standard deviation; SFI, SS flare index; SF-36, short form 36; PCS, physical component score; SOC, standard of care.
Table 2 Belimumab effects on primary and secondary endpoints in BLiSS-52
BLISS 52: endpoints SOC + placebo  
(N = 287)
SOC + belimumab  
1 mg/kg (N = 288)
P SOC + belimumab  
10 mg/kg (N = 290)
P
SRi at week 52, n (%)* 125 (44) 148 (51) 0.013 167 (58) 0.0006
• SS $ 4-point reduction (%)** 132 (46) 153 (53) 0.019 169 (58) 0.0024
• #0.3-point PGA worsening (%) 199 (69) 227 (79) 0.0078 231 (80) 0.0048
• No new 1A/2B BiLAG (%) 210 (73) 227 (79) 0.086 236 (81) 0.018
Mean % PGA improvement at week 24** 22 30 0.034 37 0.0001
SFI flare, % (HR)/median time to  
first flare, days
80/84 71 (0.75)/126 0.0026 71 (0.76)/119 0.0036
Severe SFI flare at 52 weeks, % (HR)** 23 18 (0.76) 0.13 14 (0.57) 0.0055
New 1A/2B BiLAG, % (HR) 30 27 (0.89) 0.48 19 (0.58) 0.0016
Prednisone dose reduction from 7.5 mg/day  
at baseline, by 25% or to #7.5 mg/day,  
during weeks 40–52, n (%)**
23 (12) 42 (21) 0.025 38 (19) 0.053
Prednisone dose increase from #7.5 mg/day  
to 7.5 mg/day at week 52, n (%)
34 (36) 25 (30) 0.56 17 (20) 0.020
SF-36 PCS change from baseline  
at week 52, mean (SD)
+3.0 (0.5) +4.2 (0.5) ,0.05 +4.2 (0.5) ,0.05
FACiT-fatigue score change from  
baseline at week 52, mean (SD)
+2.1 (0.6) +3.9 (0.6) ,0.001 +4.8 (0.6) ,0.001
Notes: *Primary endpoint; **Prespecified secondary endpoints.
Abbreviations: BLiSS, belimumab international SLe study; SRi, systemic response index; SS, SeLeNA-SLeDAi; PGA, physician’s global assessment; HR, hazard ratio;   
SD, standard deviation; SFI, SS flare index; SF-36, short form 36; PCS, physical component score; SOC, standard of care.
SS reductions showed a greater treatment effect on SRI 
rates for belimumab compared to placebo in both BLISS 
cohorts.26,34 Whether raising the SS threshold for improve-
ment in disease activity would be truly meaningful remains to 
be addressed in future trials. Furthermore, the less favorable 
outcomes in BLISS-76 could be congruent with the notion 
that belimumab is less effective in mice and perhaps humans 
with late, established disease.7 Indeed, decreased efficacy of 
belimumab, despite B-cell depletion, was observed in lupus-
prone mice once autoreactive T cells and dendritic cells had Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 4 Belimumab’s effects on primary and secondary endpoints in BLiSS-76
BLISS 76: endpoints SOC + placebo  
(N = 275)
SOC + belimumab  
1 mg/kg (N = 271)
P SOC + belimumab  
10 mg/kg (N = 273)
P
SRi at week 52, n (%)* 93 (34) 110 (41) 0.104 118 (43) 0.021
• SS $ 4-point reduction (%)** 98 (36) 116 (43) 0.087 128 (47) 0.006
• #0.3-point PGA worsening (%) 173 (63) 197 (73) 0.012 189 (69) 0.126
• No new 1A/2B BiLAG (%) 179 (65) 203 (75) 0.011 189 (69) 0.319
SRi at week 76, n (%)** 89 (32.4) 106 (39.1) 0.13 105 (38.5) 0.11
SS $ 4-point reduction at week 76 (%) 93 (33.8) 114 (42.1) ns 113 (41.4) ns
Mean % PGA improvement at week 24** 26.2 28.1 0.514 27.6 0.468
SFI flare, % (HR)/median time to first flare, days 83/82 79 (0.89)/85 0.232 79 (0.93)/84 0.479
Severe SFI flare, % (HR) 24 16 (0.64) 0.023 18 (0.72) 0.086
SFI flare at weeks 24–76, % (HR) 81.2 75.9 (0.84) ns 73.3 (0.78) ,0.05
Severe SFI flare at weeks 24–76, % (HR) 21.8 12.7 (0.55) ,0.01 15.7 (0.70) ns
New BILAG 1A/2B flare, % (HR) 34 28 (0.78) 0.119 32 (0.93) 0.613
Prednisone dose reduction from 7.5 mg/day  
at baseline, by 25% or to #7.5 mg/day, 
during weeks 40–52, n (%)
16 (13) 25 (19) 0.203 20 (17) 0.532
Prednisone dose reduction from 7.5 mg/day  
at baseline, by 25% or to #7.5 mg/day,  
during weeks 64–76, n (%)
22 (17.5) 35 (26.9) ns 29 (24.2) ns
Prednisone increase from #7.5 to 7.5 mg/day  
at week 52, n (%)
48 (32) 33 (23) 0.109 45 (29) 0.608
Prednisone increase from #7.5 to 7.5 mg/day  
at week 76, n (%)
27 (18.1) 19 (13.5) ns 18 (11.8) ns
SF-36 PCS change from baseline  
at week 52, mean (SD)
+2.85 (0.5) +4.37 (0.5) 0.012 +3.41 (0.47) 0.51
FACiT-fatigue score change from baseline  
at week 52, mean (SD)
+2.86 (0.66) +5.76 (0.66) 0.002 +4.63 (0.63) 0.138
FACiT-fatigue score change from baseline  
at week 76, mean
+3.16 +5.23 ,0.05 +5.0 ns
Notes: *Primary endpoint; **Prespecified secondary endpoints.
Abbreviations: BLiSS, belimumab international SLe study; SRi, systemic response index; SS, SeLeNA-SLeDAi; PGA, physician’s global assessment; HR, hazard ratio;   
SD, standard deviation; SFI, SS flare index; SF-36, short form 36; PCS, physical component score; SOC, standard of care.
formed and multiple active   amplification pathways had been 
established.7
Several secondary endpoints of disease activity and 
flares were examined, with varied results in the two trials. 
Consistent with achievement of significant SRI rates in 
BLISS-52 were changes in disease activity indices, including 
SS and PGA. The percentage of patients achieving a 4-point 
reduction from baseline in SS score at week 52, the mean 
percentage change from baseline in PGA at week 24, and 
the percentage of patients having #0.3 PGA worsening from 
baseline at week 52 were all significantly higher for both beli-
mumab groups compared to placebo (Table 2).31 Similarly, 
in combined analysis of the two BLISS trials, changes in the 
individual components of the SRI at 52 weeks were statisti-
cally significant for both belimumab groups compared to 
placebo (Table 3).33 Additionally, mean changes in PGA were 
statistically significant compared to placebo for the combined 
10 mg/kg group at 24 weeks and for both belimumab groups 
in 52 weeks (Table 3).33 Effects on secondary endpoints were, 
however, more limited in BLISS-76 (Table 4). A trend in 
the percentage of patients with a 4-point reduction in SS at 
week 52 was observed in the 1 mg/kg group (P = 0.087), 
reaching statistical significance over placebo in the 10 mg/kg 
group (P = 0.006).32 The percentage of patients having #0.3 
PGA worsening at week 52 was statistically increased over 
placebo only for the 1 mg/kg group (P = 0.012). No differ-
ence in the percentage improvement in PGA at week 24 
was observed in the treatment arms compared to placebo 
(Table 4).32
Considering that some SLE manifestations, like 
  thrombocytopenia, may be more susceptible to belimumab, 
the distribution of SS and BILAG domain scores in the 
BLISS trials is of great interest.12 Changes in particular 
organ domains were recently published for the combined 
BLISS cohort. Significant improvement from baseline at 
week 52 was noted in the central nervous system, vascular, 
  musculoskeletal, immunologic, and dermal domains of SS 
with belimumab compared to placebo.29 Among patients Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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without involvement in a specific organ system at baseline, 
there was significantly less worsening at week 52 in the 
immunologic, renal, and hematologic domains. A significant 
improvement from baseline at week 52 was noted in the 
musculoskeletal and mucocutaneous domains and a trend 
(P , 0.07) in the vasculitis BILAG domain with belimumab 
compared to placebo. There was also significantly less wors-
ening in the hematology BILAG domain and a favorable 
trend in the vasculitis and renal domains.29
Significant improvements were seen in both belimumab 
groups of BLISS-52 in the SFI flare rate and time to first 
flare, although the severe SFI flare rate and the rate of new 
BILAG 1A/2B scores at 52 weeks were significantly reduced 
only in the 10 mg/kg belimumab group (Table 2).31 In the 
combined BLISS trials data analysis, the SFI flare rate, the 
severe SFI flare rate, and the time to first flare were statistically 
improved for both belimumab groups, whereas new BILAG 
1A/2B and new BILAG 1A score rates were reduced only in the 
10 mg/kg belimumab group compared to placebo (Table 3).33 
In BLISS-76, the SFI flare rate and the time to first flare did 
not, however, differ in either belimumab group, whereas the 
severe SFI flare rate was reduced in the 1 mg/kg belimumab 
group compared to placebo.32 Of note, the SFI flare rate at 
weeks 24–76 was significantly improved in the 10 mg/kg beli-
mumab group, whereas the severe SFI flare rate over weeks 
24–76 significantly improved in the 1 mg/kg group com-
pared to placebo (Table 4).34 No difference in the rate of new 
BILAG 1A/2B scores was noted in BLISS-76 (Table 4).32,34 
Secondary outcomes should, nonetheless, be interpreted with 
caution, bearing in mind the usually   inadequate statistical 
power for their determination. The inverse dose–response 
relationship for some of the observed results further underlines 
the effects of random variation and multiple comparisons in 
studies with multiple endpoints.35 In the absence of a reason-
able, biologically plausible explanation, such differences may 
well be the result of chance.
In BLISS-52, a steroid-sparing effect of the   belimumab 
was observed among patients on 7.5 mg of daily   prednisone 
at baseline, who had their average dose reduced by 25% or 
to #7.5 mg/day during weeks 40–52 (Table 2).31 Among 
patients on #7.5 mg/day at baseline, significantly fewer 
patients increased their prednisone dose to 7.5 mg/day at 
week 52 in the 10 mg/kg belimumab group (P = 0.02   compared 
to placebo) (Table 2).31 In combined BLISS trials analysis, 
the same steroid-sparing effect was observed during weeks 
40–52 for subjects on 7.5 mg/day of prednisone at baseline 
(P , 0.05 for both belimumab groups compared to placebo) 
(Table 3).32,33 There was no difference between groups, in the 
percentage of patients on ,7.5 mg daily at baseline that 
increased their steroid dosage at week 52.33 Nonsignificant 
differences in these endpoints were,   however, observed 
among belimumab and placebo in BLISS-76 (Table 4).32,34
Patient-reported outcomes pertinent to HRQoL were 
complementary to physician-centered indices in the BLISS 
trials.36,37 Mean improvement from baseline in SF-36 PCS at 
week 24, a major prespecified endpoint, did not differ between 
treatment arms and placebo in any of the BLISS   trials.38 In 
BLISS-52, differences in PCS, physical   functioning, and 
bodily pain were significant at 52 weeks for both belimumab 
groups compared to placebo (Table 2).30 Both belimumab 
groups in this study demonstrated   significant improvement 
in FACIT-Fatigue scores by week 52 compared to placebo 
(Table 2), with an early sustained response observed in 
the 10 mg/kg belimumab group (P = 0.0015 at 8 weeks, 
P = 0.024 at 36 weeks, and P = 0.0003 at 52 weeks compared 
to placebo).30 Similar significant improvements in SF-36 
PCS at 52 weeks and in FACIT-Fatigue at 52 and 76 weeks 
were observed in the 1 mg/kg belimumab group of BLISS-76 
(Table 4).32,34 On the pooled BLISS data analysis, the mean 
change from baseline in SF-36 PCS and FACIT-Fatigue 
scores at 52 weeks were statistically significant for both 
belimumab groups compared to placebo (Table 3).38
Despite the not always substantial improvements in 
clinical outcomes, changes in immunologic parameters 
were impressive in the BLISS trials.39 Significant reduc-
tions in immunoglobulins (immunoglobulin G [IgG], 
  immunoglobulin M (IgM), immunoglobulin A [IgA]) 
(P , 0.0001 for both   belimumab groups) and   autoantibodies 
(anti-dsDNA IgG, anti-Sm IgG, anti-ribosomal P IgG 
[P = 0.0001, ,0.005, 0.02, respectively, for the 1 mg/kg 
group and ,0.0001 for the 10 mg/kg group], anti-cardiolipin 
IgA [P = 0.01 for the 10 mg/kg group]) and normalization 
in hyperglobulinemia (1618 g/L) (in 50% of the 1 mg/kg 
group and 48.9% of the 10 mg/kg group versus 19.1% in 
placebo [P , 0.0001]) were noted at 52 weeks for both 
belimumab groups of BLISS-52 compared to placebo.39 
Similar were the effects on   seroconversion rates at week 
52 for patients seropositive for anti-dsDNA, anti-Sm, anti-
ribosomal P, and/or   anti-cardiolopin (IgG + IgM) antibodies 
at baseline (P = 0.01 for the 10 mg/kg group; results in the 
1 mg/kg group reached significance only for anti-dsDNA, 
anti-ribosomal P, and anti-cardiolipin IgG antibodies).39 In 
the pooled analysis of BLISS trials, similar results were 
observed.40 Median percentage reductions in anti-dsDNA, 
anti-Sm, anti-cardiolipin IgG, and anti-P antibody serum 
levels and seroconversion rates from positive to negative Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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were statistically significant for both belimumab doses 
compared to placebo.40 Significant median percent reduc-
tions of baseline anti-dsDNA levels at 76 weeks were 
also observed in both belimumab groups of BLISS-76 
(P , 0.0001 compared to placebo).34   Seroconversion from 
positive to negative anti-dsDNA was significant only in 
the 1 mg/kg belimumab group.34 Given the correlations 
of   anti-dsDNA titers with BLyS levels and SLE disease 
  activity, post-hoc exploratory analysis of clinical responses 
in this patient subgroup would be of interest.
Consistent with the effects of belimumab on antibody 
production were changes in complement components known 
to have a major role in antibody-mediated tissue damage 
and SLE disease activity. Significantly greater increases 
in C3 and C4 levels and a higher % normalization of low 
C3 and C4 were noted in belimumab-treated patients com-
pared to placebo-treated patients at 52 weeks in BLISS-52 
(P , 0.005 for both belimumab groups, except nonsig-
nificant %   normalization of C3 with belimumab 1 mg/kg 
compared to placebo).39 Similar increases and normaliza-
tion in C4 titers were observed with belimumab compared 
to placebo in BLISS-76 (P , 0.0001 and P , 0.001 for 
belimumab 10 and 1 mg/kg, respectively, compared to 
  placebo), whereas significant changes and normalization 
in C3 titers were noted only in the 10 mg/kg group.34 In 
pooled data analysis, belimumab-treated patients had sig-
nificantly greater increases in C3 and C4 levels (P , 0.05 
compared to placebo), and a dose–response relation was 
observed.40
In accordance with results of animal studies and 
the phase II belimumab trial, significant reductions in 
CD20+ B cells (including CD20+/CD27− naive cells, 
CD20+/CD69+ activated cells, and CD20+/CD138+ plasma-
cytoid cells) were observed with belimumab over placebo in 
BLISS-76.34 CD20−/CD138+ plasma cells, CD20−/CD27hi 
short-lived plasma cells, and CD19+/CD27hi/CD38hi cell 
subsets showed similar reductions from baseline, significant 
only in the 10 mg/kg group compared to placebo. On the 
contrary, increases in CD20+/CD27+ memory cells were 
noted, reaching statistical significance in the 10 mg/kg group 
compared to placebo.34 Regarding effects on T cells, signifi-
cant increases in CD3+/4+, CD3+/8+, and total CD3+ subsets 
at 76 weeks were observed with belimumab compared to 
  placebo.34 Significant reductions of various circulating B-cell 
subsets, but not T-cell subsets, were similarly observed in the 
combined analysis of the belimumab trials.40 Memory B cells 
increased 100% by week 8 and gradually decreased toward 
baseline levels through week 52. A modest expansion of T-cell 
subsets was observed at week 52, but this is considered to be 
a secondary effect of the B-cell reductions.40
Changes in immunologic parameters, although 
  concordant, did not translate to such impressive changes 
in disease   activity, highlighting the biological complexity 
of SLE. Multiple pathways are contributory to histologic 
damage and   clinical disease in SLE, not all of which are 
sensitive to BLyS.   Inflammation accelerated by INFa was 
resistant to BLyS blockade in animal models.7 Interactions 
of B cells with T cells and other cell types significantly 
influence response to BLyS blockade as suggested by the 
enhanced efficacy of combined B- and T-cell inhibition 
in murine lupus.11   Autoantibody production by long-lived 
plasma cells is independent of BLyS and thus resistant 
to BLyS blockade.7,12 Accordingly, the clinical effects of 
therapeutic BLyS neutralization may vary widely across the 
heterogeneous population of SLE.
Compounding  its  clinical  efficacy,  belimumab 
  demonstrated a favorable safety profile in the BLISS trials, an 
argument favoring its use over other commonly   administered 
immunosuppressive drugs in SLE.2 In both BLISS-52 and 
BLISS-76, the overall rates of adverse events, deaths,   serious 
adverse events, infections, and laboratory abnormalities 
were comparable among belimumab and placebo.26,31,32,34 
A slightly higher risk of hypersensitivity infusion reactions 
was reported in BLISS-52 (1.6% with belimumab compared 
to 0.3% with placebo).26,31 Comparably, serious and severe 
infusion reactions were modestly increased with belimumab 
compared to placebo in BLISS-76 (1.1% in the 10 mg/kg 
group vs 0.4% in placebo).32,34 No malignancies were reported 
in BLISS-52, whereas six occurred in BLISS-76 (one on 
placebo, four on 1 mg/kg, two on 10 mg/kg).26,32,34 Further 
insight into belimumab’s safety is expected by extension of 
the BLISS trials.
Belimumab’s effects on antibody production to 
  pneumococcal, tetanus, and influenza vaccines, administered 
prior to study entry, were examined in BLISS-76.41 Patients 
receiving a pneumococcal (n = 73) or tetanus (n = 81) 
  vaccine within 5 years or an influenza vaccine (n = 146) 
within 1 year prior to study entry were tested for vaccine 
antibody levels (IgG) at baseline and week 52. Endpoints 
included the percentage change in antibody levels from 
baseline to week 52 in patients with preexisting antibodies 
and the proportion of patients with protective antibodies 
at baseline who maintained protective levels at week 52. 
Consistent with the preservation of the memory B-cell com-
partment (CD20+/27+ B cells), belimumab did not cause a 
statistically significant decrease in preexisting antibodies to Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  pneumococcal and tetanus vaccines. Most patients were able 
to maintain   protective titers to these vaccines, and changes 
were similar across treatment groups. Preexisting antibody 
responses to seasonal influenza vaccines were generally 
not affected by belimumab, although a statistical, but not 
  clinically relevant, difference (less than onefold median 
change in titer) between treatment groups was observed for 
some antigens. The percentage of patients that maintained 
protective specific titers at the end of 52 weeks was similar 
in the belimumab and placebo treatment groups.41
extension studies
In parallel with the BLISS trials, a 5-year extension, 
  uncontrolled arm of the phase II belimumab study has 
generated additional data on efficacy and safety over 
1415   patient-years of exposure.42,43 In an initial 24-week 
extension phase beginning at week 56, placebo subjects 
were administered belimumab 10 mg/kg, while the dose in 
belimumab-treated patients was maintained or increased to 
10 mg/kg. A total of 19% of patients dropped out during 
the placebo-controlled portion of the study, whereas 296 
were enrolled at week 80 in the open-label, uncontrolled 
extension phase of belimumab at 10 mg/kg administered 
every 28 days. The study discontinuation rate was 3%–9% 
per year. The baseline characteristics of patients remaining 
in the trial were similar to those that discontinued the drug. 
Safety was monitored monthly with reporting of adverse 
events and flare rates in 6-month intervals. The SS, SFI, 
and SRI were utilized for measurements of disease   activity. 
All efficacy assessments were limited to the seroposi-
tive patient subgroup (n = 321), who were similar to the 
patients enrolled in the phase III trials. SRI was reached in 
46% seropositive belimumab-treated patients at 1 year (vs 
29% in placebo, P , 0.05), and response was sustained in 
55%–59% from 1.5 to 5 years.42,43 The slow onset, sustained 
improvement over time was consistent with belimumab’s 
latency in B-cell depletion. The frequency of new 1A/2B 
BILAG flares decreased from 30% at 0.5 year to 23% 
at 1 year (vs 33% and 25%, respectively, with placebo) 
and to 11% at 5 years; flares by SFI decreased from 72% 
(severe 13%) at 0.5 year to 62% (severe 8%) at 1 year (vs 
76% [severe 9%] and 73% [severe 11%], respectively, with 
placebo) and to 22% (severe 1.6%) at 5 years. A steroid-
sparing effect of belimumab 10 mg/kg on seropositive 
patients was noted, as the   proportion of patients that 
decreased their prednisone dose to ,7.5 mg/day contin-
ued to increase over 3 years, whereas the proportion of 
patients requiring a steroid dose increase remained low.44 
The   incidence of adverse effects was generally stable or 
decreased over 5 years.42
Longitudinal  measurements  of  antibody  and 
  immunoglobulin titers and complement levels over 3 years 
were compatible with improvements in SLE disease   activity 
and consistent with immunologic changes in the BLISS 
trials.45 Maximal median reductions of immunoglobulin 
isotypes were reached in the first 8–24 weeks and stabilized 
or further declined with continued belimumab treatment. 
Among patients with hypergammaglobulinemia, 47% 
  normalized on belimumab at week 52 (P = 0.0062 compared 
to placebo) and up to 57% over 3 years. Complement levels 
increased in all SLE patients with low levels at baseline who 
got treated with belimumab. Belimumab-treated patients were 
more likely, than placebo, to have a significant decrease in 
anti-dsDNA antibodies ($50% or conversion to   negative) 
(30% vs 17% at 52 weeks, P = 0.015), a difference that was 
further increased at week 160 (47%). The percentage of 
patients with significant anti-dsDNA reduction was higher in 
clinical responders (using SRI) than nonresponders (P , 0.05 
at weeks 52 and 128). Seroconversion rates for anti-Sm or 
anti-RNP antibodies over weeks 52–160 were, however, 
not significantly different for belimumab-treated patients 
(anti-Sm: P = 0.0805, anti-RNP: P = 0.1837 compared to 
placebo at week 52). Effects on B-cell subsets over 2 years 
of treatment were examined in 17 seropositive patients of the 
initial cohort.46 The total number of B cells started to decrease 
from baseline between days 84 and 168 due to decrease in 
naive and transitional B cells. CD27+IgD+ memory B cells 
and plasmablasts decreased only after 532 days, whereas 
CD27+IgD− memory B cells were not affected, and there 
were no changes in T cells.
Two open-label, parallel assignment continuation   studies 
(NCT0072486747 and NCT0071293348) of patients completing 
the BLISS-52 or BLISS-76 trials are ongoing, with projected 
completion in December 2010, primarily examining beli-
mumab’s long-term safety. Additional secondary endpoints in 
NCT00724867 include disease activity assessments, quality of 
life measures (SF-36 Health Survey and FACIT-Fatigue scale), 
and effects on the SLICC/ACR Damage Index, anti-dsDNA 
and serum complement levels, prednisone use, proteinuria, 
serum immunoglobulin G, and B-cell subsets. In both 
studies, belimumab is administered in an open-label, uncon-
trolled fashion as 1 or 10 mg/kg IV infusion every 28 days. 
  Furthermore, a phase II multicenter, randomized, open-label 
trial of subcutaneously administered belimumab in SLE 
patients is underway (NCT00732940).49 Two dosing schedules 
of belimumab, 100 mg every other week or 100 mg three times Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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a week, administered for 6 months are examined. Primary 
endpoints include adverse events and changes from baseline 
in B cells and B-cell subsets at weeks 12 and 24. Secondary 
endpoints include belimumab concentrations following sub-
cutaneous administration and changes from baseline at weeks 
12 and 24 in PGA score, SS, serum immunoglobulins, C3/C4 
levels, anti-dsDNA levels, and lipid profile.
Conclusions
Belimumab, a BLyS-specific inhibitor, has shown   encouraging 
results in large RCTs in SLE. Completion of the primary 
and several secondary endpoints for both belimumab doses 
in BLISS-52 and the smaller, but still significant, effects 
observed in BLISS-76 certainly represent major accom-
plishments. Amidst a limited range of therapeutic options 
for a disease as complex as SLE, very few of which are 
FDA approved, the pending FDA review on belimumab is 
eagerly anticipated.
Belimumab may possibly be the first biologic to be 
approved in SLE. Further analysis of the BLISS trials 
and mechanistic studies in the patients enrolled should 
be   encouraged to define its best use. Furthermore, critical 
review of the BLISS trials, as well as some of the negative 
SLE   trials so far, may help provide insight into efficient SLE 
trial design that will set the stage for more effective therapies 
of this disease.
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